ISSN: 0975-0851
Statistical considerations in biosimilar assessment using biosimilarity index
In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation
View More »
Journal of Bioequivalence & Bioavailability received 4890 citations as per Google Scholar report
Research Article
An Open Label, Balanced, Randomized, Two Treatments, Two Sequences, Two Periods, Crossover, Single Dose, Bioequivalence Study of Olmesartan medoxomil/Hydrochlorothiazide 20 mg/12.5 mg Coated Tablets of Abbott and Olmetec plus® (Olmesartan medoxomil/Hydrochlorothiazide) 20 mg/12.5 mg Coated Tablets of Daiichi-Sankyo in Healthy, Adult, Human Subjects Under Fasting Condition
DOI: 10.35248/0975-0851.23.15.538
Review Article
Giant Cell Arteritis after COVID-19 Vaccination along with Immuno-Pathogenesis of this Entity
DOI: 10.35248/0975-0851.23.15.544
Pharmacokinetic/Pharmacodynamic Model for Aptensio XR® (an Extended-Release Methylphenidate Formulation) in 6-12 year-old Children
DOI: 10.35248/0975-0851.22.15.539
Opinion Article
The Crucial Role of Transporters in Drug Disposition and Metabolism
DOI: 10.35248/0975-0851.15.13.540
Perspective
Improving Cancer Treatment by Using the Potential of Bioequivalence in Anticancer Therapies
DOI: 10.35248/0975-0851.15.13.542
Bioequivalence in Antidiuretics and the Therapeutic Precision Revolution
DOI: 10.35248/0975-0851.15.13.541
Commentary Article
Improving Therapeutic Quality by Reducing Formulation in Drug Development
DOI: 10.35248/0975-0851.15.13.543